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Background
We had revealed that C-type natriuretic peptide (CNP) is
a potent stimulator of endochondral bone growth by
using transgenic and knockout mice: transgenic mice with
targeted overexpression of CNP in cartilage develop
prominent skeletal overgrowth [1], whereas mice
depleted with CNP exhibit impaired endochondral bone
growth [2]. We planned to translate this effect of CNP into
the therapy for skeletal dysplasias, of which the effective
drug therapy is not established yet. Here we investigated
the effect of CNP on the impaired bone growth of mice
model of achondroplasia, the most common form of skel-
etal dysplasias.
Results
First, we investigated the effects of plasma CNP on
impaired bone growth in achondroplastic mice that spe-
cifically overexpress CNP in the liver under the control of
human serum amyloid P component promoter. Increased
plasma CNP stimulated the impaired growth of achon-
droplastic bones, and they grew almost comparable to
those of wild type mice at the age of 6 weeks. Then we
treated achondroplastic mice with continuous intrave-
nous infusion of CNP at the dose of 1 g/kg/min, and suc-
cessfully rescued the shortness of most bones formed
endochondral ossification at the end of 3-week experi-
mental period. Figures 1 and 2.
Conclusion
Our results indicate that treatment with CNP is a potential
therapeutic strategy for skeletal dysplasias, including
achondroplasia, in humans.
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Soft x-ray picture of wild type mice (Wt), achondroplastic  model mice (Ach), and achondroplastic model mice treated  with CNP at the dose of 1 g/kg/min Figure 1
Soft x-ray picture of wild type mice (Wt), achondro-
plastic model mice (Ach), and achondroplastic model 
mice treated with CNP at the dose of 1 g/kg/min.Publish with BioMed Central    and   every 
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Lengths of bones measured on soft x-ray film.